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Charge transfer interaction of organic p-acceptors with
the anti-hyperuricemic drug allopurinol: Insights from IR, 
Raman, 1H NMR and 13C NMR spectroscopies
The topic of charge-transfer (CT) complexation of vital 
drugs has attracted considerable attention in recent years 
owing to their significant physical and chemical proper-
ties. In this study, CT complexes derived from the reac-
tion of the anti-hyperuricemic drug allopurinol (Allop) 
with organic p-acceptors [(picric acid (PA), dichlorodi-
cyanobenzoquinone (DDQ) and chloranil (CHL)] were 
prepared, isolated and characterized by a range of phys-
icochemical methods, such as IR, Raman, 1H NMR and 
13C NMR spectroscopy. The stoichiometry of the com-
plexes was verified by elemental analysis. The results 
show that all complexes that were formed were based on 
a 1:1 stoichiometric ratio. This study suggests that the 
complexation of Allop with either the DDQ or CHL ac-
ceptor leads to a direct p®p* transition, whereas the mol-
ecules of Allop and PA are linked by intermolecular hy-
drogen-bonding interactions.
Keywords: allopurinol, p-acceptor, charge-transfer, pro-
ton-transfer
Allopurinol (Allop, 4-hydroxypyrazolo-[3,4-d]-pyrimidine, Fig. 1), an anti-hyperurice-
mic drug, is a structural isomer of hypoxanthine (6-hydroxypurine), which is both a sub-
strate and an inhibitor for xanthine oxidase (1). It is rapidly oxidized in vivo to 4,6-di-
hydroxy pyrazolo[3,4-d]pyrimidine (oxypurinol), which is a structural isomer of xanthine 
(2,6-dihydroxypurine) and which is excreted in the urine (1). Allop has been used in mod-
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ern therapy of gout and prevention of the tumor lysis syndrome (2, 3). Allop is currently 
in the first line urate-lowering treatment, prescribed for patients with guidelines and 
chronic gout recommendations, starting at a low dose and titrating it upwards until a 
target urate level is reached (4, 5). Also, Allop acts as a scavenger for toxic hydroxyl free 
radicals and chelates non-protein-bound (pro-radical) iron (6). It has been found to reduce 
free-radical formation in both pig and human fetuses (7). Studies have also shown that 
Allop effectively protects the brain from ischemia and reperfusion-induced injuries caused 
by oxidative stress in the brain, intestine, kidney and heart (8, 9).
Studies of the charge-transfer (CT) or proton-transfer (PT) interactions of drugs have 
attracted considerable interest and have become a popular area of research because of their 
unique physical and chemical properties and wide range of applications (10). The chemis-
try of these interactions has received considerable attention in pharmacology, chemistry, 
biology and medicine. They play crucial roles in many processes; therefore, understanding 
these interactions is important for the understanding of drug-receptor binding and the 
drug’s mechanism of action as well as for obtaining quantitative estimates of drugs (10–12).
During the last decade, considerable efforts were focused on the interactions between 
drugs or organic donors and acceptors both in the solid state and in solution. For example, 
Singh and Ahmad (13) studied the interaction between p-nitroaniline as a donor and ben-
zoic acid as an acceptor in different polar solvents. Selvakumar et al. (14) studied the optical 
and thermal properties of a 3-nitroanilinium trichloroacetate as a new CT complex, where-
as Singh et al. (15) prepared a new CT crystal by the interaction between 2,2′-bipyridine as 
a donor and 3,5-dinitrosalicylic acid as an acceptor. Adam (16) synthesized new nano-struc-
tured complexes from the reactions between reserpine and quinidine with chloranilic acid. 
For several years, our group investigated the synthesis, characterization and application of 
various CT and PT interactions. For example, the interactions between theophylline (10) and 
metronidazole (17) with different types of σ- and π-acceptors were studied. In our previous 
study, we determined the content of Allop in some pharmaceutical preparations spectro-
photometrically via CT interaction between Allop and 3,6-dichloro-2,5-dihydroxy-p-benzo-
quinone and 2,3-dichloro-5,6-dicyano-p-benzoquinone in acetonitrile (18).
As a continuation of this study, and as a part of our continuing interest in this field, in 
this work, we originally report the structural chemistry of CT complexes formed by inter-
molecular interactions of Allop with the organic p-acceptors [i.e., picric acid (PA), 2,3-di-
chloro-5,6-dicyano-1,4-benzoquinone (DDQ) and chloranil (CHL)] in 1:1 methanol-chloro-
form as a binary solvent system, in order to provide basic data that can be used to determine 
Allop in pharmaceutical preparations using different acceptors and different solvents.
EXPERIMENTAL
Reagents and equipments
All the chemicals used were of analytical grade and were used as purchased without 
further purification. Allopurinol (purity > 99 %) and the organic acceptors, picric acid 
(purity ³ 98 %), 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (purity > 98 %) or chloranil 
(purity ³ 99 %) (Fig. 1) were purchased from Sigma-Aldrich Chemical Co. (USA).
C, H and N were analyzed using a Perkin-Elmer 2400 series CHN micro analyzer 
(USA) in order to obtain the stoichiometry of the interaction. The IR spectra of the products 
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(KBr discs) were measured at room temperature using a Shimadzu FT-IR spectrophotom-
eter (Japan) over the range of 4000–400 cm–1 with 30 scans at 2 cm–1 resolution. The Raman 
laser spectra of the products were acquired on a Bruker FT-Raman spectrophotometer 
equipped with a 50-mW laser (Bruker, Germany). 1H and 13C NMR spectra were collected 
on a Bruker DRX-250 spectrometer operating at 600 MHz (Bruker). Measurements were 
performed at ambient temperature using dimethylsulfoxide (DMSO-d6) as the solvent and 
tetramethylsilane (TMS) as the internal reference.
Syntheses
A typical procedure for the preparation of CT complexes is briefly described as fol-
lows. First, 2 mmol of Allop donor (in three beakers) and 2 mmol of each acceptor (PA, 
DDQ or CHL) were dissolved separately in 20 mL of a 1:1 methanol-chloroform mixture. 
The solutions were heated until completely dissolved. The Allop donor and the PA, DDQ 
and CHL acceptors were completely dissolved in 20 mL of a solvent mixture (methanol-
Fig. 1. Chemical structures of drug allopurinol (Allop) and the organic p-acceptors: picric acid (PA), 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and chloranil (CHL).
Table I. Elemental analyses of the synthesized CT complexes
Compound Molecular formula Mr
Elemental analysis (%)
ColorC H N
Found Calc. Found Calc. Found Calc.
Allop free C5H4N4O 136.11 44.00 44.08 2.91 2.94 41.25 41.14 White
Allop-PA 
complex C11H7N7O8 365.21 35.97 36.14 1.88 1.92 26.90 26.83 Light yellow
Allop-DDQ 
complex C13H4Cl2N6O3 363.11 43.05 42.96 1.17 1.10 22.98 23.13 Reddish-brown
Allop-CHL 
complex C11H4Cl4N4O3 381.99 34.61 34.55 1.00 1.05 14.73 14.66 Yellowish-brown
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chloroform, 1:1) at 60 °C. Then the solution of the Allop donor was added to the solution of 
each acceptor. The resulting mixtures were stirred at room temperature for approximately 
0.5 h. Allop-PA, Allop-DDQ, and Allop-CHL products precipitated as light yellow, red-
dish-brown and yellowish-brown solid, respectively. The formed products were isolated, 
filtered, and further purified using the solvent mixture to obtain pure products. The prod-
ucts were then collected and dried in vacuo for 48 h.
RESULTS AND DISCUSSION
Stoichiometry of the interaction
Elemental analyses, molar ratio and color of the synthesized CT complexes are shown 
in Table I. The stoichiometry of the interaction between the drug Allop and the acceptors 
(PA, DDQ or CHL) was found to be 1:1, so the structures of the CT complexes were formu-
lated to be [(Allop+)(PA-)], [(Allop)(DDQ)] and [(Allop)(CHL)].
Spectral characterization
Structures of the synthesized CT complexes have been confirmed by IR, 1H and 13C 
NMR spectral data. The data obtained by these techniques are consistent with each other 
and support the suggested structures.
Vibrational spectroscopy. – Table II shows characteristic IR spectral bands of free Allop 
and its CT complexes. The IR spectrum of free Allop was characterized by principal ab-





– 3448m –  n(+N-H …O-)
3167ms 3166m 3161w 3166w n(N-H); of Allop
– 2693m –  n(N-H …O)
– – 2228m  n(C≡N)
1765m 1765w 1744w 1736w nas(C=O)
1699s 1700vs 1704vs 1689vs ns(C=O)
1593s 1592vs 1596vs 1590s ddef(N-H); of Allop
1479s 1431ms 1477ms 1479ms n(C=N); of Allop
1388ms 1366m 1362m 1364m n(C=C)
1235s 1236s 1227s 1232ms nas(C-N)
s – strong, w – weak, m – medium, v – very, 
n – stretching, ns – symmetrical stretching, nas – asymmetrical stretching, d – bending.
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sorption peaks at 3167 cm–1 for n(N-H), 2992, 2943 and 2871 cm–1 for C–H symmetric and 
asymmetric stretching, 1765 and 1699 cm–1 for n(C=O), 1593 cm–1 for ddef(N-H), 1479 cm–1 for 
n(C=N), 1388 cm–1 for n(C=C) and 1235 cm–1 for n(C–N). The IR spectrum of the Allop-PA 
complex is characterized by a medium band at 2693 cm–1. This band is attributed to n(+N-H) 
and confirms migration of the PA proton towards the nitrogen (C=N) of the Allop pyrazole 
ring to form an intermolecular H-bonded ion pair (+N-H…O-). In general, intermolecular 
H-bonding in the proton-transfer complex is expected at around 3400 cm–1 (19). The bands 
observed at around 3448 cm–1 are due to the stretching vibration of +N-H …O- and are the 
evidence of hydrogen bonding in these complexes. In addition, the characteristic band of 
n(C=N) vibration observed at 1479 cm–1 in the spectrum of free Allop shifts to ~1431 cm–1 
in Allop-PA. The observed shift of the n(C=N) band upon complexation suggests that this 
group participated directly in complexation. All these observations indicate the presence 
of hydrogen bonding in this complex (13–16). When DDQ and CHL acceptor complexed 
with Allop, the vibrational frequencies n(N-H), ddef(N-H) and n(C=N) of Allop slightly 
shift, which indicates that these groups do not participate in the complexation. The cyano, 
carbonyl and chloro groups in the DDQ or CHL acceptors are electron withdrawing, re-
moving electron density from the aromatic ring and thereby causing it to become an elec-
tron-accepting moiety. Instead, Allop contains high electron density over the pyrazole ring 
(20–22). Fig. 2 shows the representative laser Raman spectra of free Allop and the Allop-PA 
complex. The Raman spectrum of the free Allop was characterized by principal absorption 
peaks at 3101 cm–1 for n(N-H), 1696 and 1609 cm–1 for n(C=O), 1577 cm–1 for ddef(N-H), 1484 
Fig. 2. Laser Raman spectra of: a) free Allop and b) its complex with picric acid.
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cm–1 for n(C=N), 1395 cm–1 for n(C=C) and 1244 cm–1 for n(C–N). The strong sharp band 
observed at 718 cm–1 is assigned to d(C-N) out-of-plane bending. The Raman spectrum for 
the PA complex showed a strong band at 1346 cm–1, which clearly corresponds to the C=C 
ring stretching mode. The vibrational modes of n(C–N) for this complex appear at 1279 
cm–1 and the intense sharp band observed at 718 cm–1 corresponds to the out-of-plane 
bending d(C-N).
1H and 13C NMR spectroscopy. – Tables III and IV show the 1H and 13C NMR chemical 
shifts (d, ppm) for Allop free and its CT complexes, respectively. Figs. 3 and 4 show the 1H 
and 13C NMR spectra of Allop-PA and Allop-DDQ complex, respectively. According to the 
1H NMR spectrum of free Allop, the proton of the pyrimidine ring N-H was observed as 
a singlet signal at 3.84 ppm, and that of pyrazole ring N-H appeared as a singlet at 12.87 
ppm (18). The signal due to the phenolic proton (–OH) of the PA acceptor, which is ob-
served at d ~11.94 ppm (10) in the spectrum of the free PA acceptor, is no longer observed. 
Instead, a new signal is located at approximately ~6.83 ppm. This singlet signal is assigned 
to the +N-H proton formed by proton transfer from the -OH group of PA to the nitrogen 
atom of the Allop pyrazole ring. The singlet peaks observed at ~8.6 and ~12.1 ppm in the 
DDQ and CHL complexes were assigned to the pyrimidine ring N-H proton and pyrazole 
ring N-H proton, respectively. We noted that the signal of the pyrimidine ring N-H proton 
showed very large shifts relative to the analogous peak in the spectrum of free Allop (3.84 
ppm). The electronic environments of Allop protons were affected by the existence of the 
CT interaction between the Allop and DDQ or CHL acceptor molecules. The 13C NMR 















Allop free 3.84 7.97 8.13 12.87 – –
Allop-PA 8.55 8.09 8.18 12.13 8.60 6.83
Allop-DDQ 8.60 8.09 8.18 12.18 – –
Allop-CHL 8.58 8.11 8.20 12.10 – –




Allop free 158.1 134.8, 147.8 105.8, 155.0
Allop-PA 160.5 124.4, 141.7 105.5, 125.0, 133.4, 147.8, 153.7, 157.6
Allop-DDQ 155.3 126.7, 141.8 115.3, 120.5, 127.4, 128.2, 128.5, 142.4
Allop-CHL 156.2 124.5, 147.4 119.2, 127.7, 131.5, 132.8
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spectrum of free Allop showed five resolved carbon signals. The appearance of nine reso-
nant carbon signals in the 13C NMR spectra of the Allop-PA and Allop-DDQ complexes, and 
seven for the Allop-CHL complex is consistent with the proposed molecular structure of 
these complexes. For all complexes, common changes in the values of 13C chemical shifts 
in Allop can be observed as a result of its complexation with organic acceptors.
Complexation pathway
In a previous study, we found that Allop forms a yellow solid complex with DDQ in 
acetonitrile via 1:1 interaction, and the CT interaction occurs through n-p* transition with 
deprotonation of NH group of Allop, to only one of the CN groups of DDQ, by forming 
intermolecular hydrogen bonding (18). In this study, however, Allop forms a reddish-
brown solid complex with DDQ in methanol-chloroform mixture, but the IR data indicate 
that the interaction occurs through p®p* transition via the pyrazole ring of Allop and the 
aromatic ring of DDQ. This difference in complexation pathway could be attributed to the 
Fig. 3. Spectra of the Allop-PA complex: a) 1H and b) 13 C spectrum.
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Fig. 4. Spectra of the Allop-DDQ complex: a) 1H and b) 13 C spectrum.
Fig. 5. Proposed structural formula of the proton-transfer complex Allop-PA and charge-transfer 
complexes Allop-DDQ and Allop-CHL (for the acronyms see above).
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solvent effect. Complexation of Allop with CHL acceptor also leads to a direct p®p* tran-
sition via the pyrazole ring of the Allop and the aromatic ring of CHL, whereas hydrogen 
bonding with proton transfer is observed between Allop and PA acceptor. Fig. 5 illustrates 
the proposed structures of Allop complexes with PA, DDQ and CHL acceptors.
CONCLUSIONS
Structures of the synthesized CT complexes have been confirmed by IR, 1H and 13C 
NMR spectral data. The data obtained by these techniques are consistent with each other 
and support the suggested structures. Our findings indicated that the molecules in the 
Allop-DDQ and Allop-CHL complexes are linked by charge-transfer interactions, where-
as the rings of Allop with PA are linked by intermolecular hydrogen-bonding interaction. 
In further investigations, we will shed some new light on the biological activities of the 
Allop CT complexes.
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